ITC Limited v. The Controller of Patents, Designs & Trademark

Every founder dreams of the moment their invention earns a patent — the ultimate badge of innovation. But what happens when the patent office says no, not because the invention lacks novelty, but because regulators are worried about what the product might do to public health? This is exactly the high-stakes standoff that played out between one of India's largest conglomerates and the country's patent authorities, a battle that would redefine how India balances innovation incentives with public welfare concerns.

ITC Limited, a household name in Indian business, filed a patent application for a novel chemical-based nicotine aerosol delivery device. Unlike conventional electronic nicotine delivery systems, ITC's invention relied purely on a chemical reaction to generate the aerosol, with no electrical components involved in its core functioning. The Controller of Patents, however, rejected the application. The rejection was not based on questions of novelty or inventiveness, but on public health concerns tied to nicotine. The Controller leaned on various domestic statutes that restrict or regulate nicotine-based products, effectively treating the public health risk as a barrier to patentability itself.

ITC Limited pushed back hard. Their core argument was technical and precise: the device in question operates entirely through a chemical reaction, meaning it contains no electrical components and therefore should not be classified as an ENDS (Electronic Nicotine Delivery System) or e-cigarette. By lumping it into categories meant for electronic devices, the Controller had applied the wrong framework. Beyond the technical classification fight, ITC raised a far more powerful legal point. They argued that denying a patent on the grounds of public health restrictions on commercial sale was fundamentally inconsistent with India's obligations under international intellectual property treaties. The Controller, on the other hand, stood by the position that allowing patents on nicotine-related products would undermine domestic public health policy, and that the patent office had a duty to factor in such concerns when examining applications.

The Calcutta High Court sided decisively with ITC Limited. The court drew a sharp and important line in the sand: patentability and commercial exploitation are two separate questions. Citing the foundational principles of the TRIPS Agreement and the Paris Convention, the court made clear that these international frameworks mandate that a patent cannot be denied merely because the commercial exploitation of the invention is restricted or prohibited under domestic law. In other words, the patent office's job is to evaluate whether an invention is novel, inventive, and industrially applicable — not to act as a gatekeeper for public health policy. By conflating the two, the Controller had overstepped. The rejection was set aside, and ITC's path to securing the patent was cleared.

For founders and IP professionals, this case delivers a critical lesson: the right to a patent and the right to commercially sell a product are governed by entirely different legal frameworks. If your invention faces regulatory headwinds or public health scrutiny, do not assume the patent office will reject your application on those grounds alone. International IP principles exist precisely to protect genuine innovation from being collateral damage in unrelated policy debates. When filing, frame your application around the technical merits of the invention, and if you face a rejection rooted in regulatory concerns, remember that the law distinguishes sharply between whether an invention deserves protection and whether it can be freely sold.